Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL

Share :

ASH 2019
Published: 10 Dec 2019
Views: 865
Rating:
Save
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Dr Patrick Brown presents data at ASH 2019 showing the improved survival of children and young adults with relapsed B-cell acute lymphoblastic leukaemia (B-ALL) when they were given blinatumomab compared with standard chemotherapy.  

Watch our interview with Dr Brown here. 

Read more about the study here. 

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )
28 Oct 2024

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar
Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )
10 Oct 2024

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India
Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )
9 Oct 2024

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )
27 Jun 2024

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )
3 Jun 2024

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation